3SLINGEKLAND M, GUCHELAAR HJ, GELDERBLOM H. Li-posomal drug formulations in cancer therapy : 15 years along theroad [ J ]. Drug Discov Today ,2012, 17(3-4): 160 -166. 被引量：1
4ALLEN TM, HANSEN CB,DEMENEZES DEL. Pharmacokinet-ics of long cir-culating liposomes[ J]. Adv Drug Deliv Rev, 1995,16(2 - 3 ) : 267 -284. 被引量：1
5NORTHFELT DW, MARTIN FJ,WORKING .,et al. Doxorubi-cin encapsu-lated in liposomes containing surface bound polyethy-lene glycol : plarmackinetics,tumor localization and safety in pa-tients with AIDS-related Kaposi, sarcoma [ J ]. J Clin Pharmacol,1996,36(1) ; 55 -63. 被引量：1
6RIFKIN RM, GREGORY SA, MOHRBACHER AN,ef al. Pegy-lated liposomal doxorubicin, vincris-tine, and dexamethasoneprovide significant reductionin toxicity compared with doxorubi-cin ,vincristine, and dexamethasone in patients with newly diag-nosedmultiple myeloma[ J]. Cancer,2006 ,106(4) ;848 - 858. 被引量：1
7KESTERSON JP,ODUNSI K, LELE S,et al. Highcumulativedoses of pegylated liposomal doxorubicin are notassociated withcardiac toxicity in patients with gynecologicmalignancies [ J ].Chemother, 2010, 56(2) : 108 -111. 被引量：1
8O,BRIEN ME,WIGLER N,INBAR M, et al. Reducedcardio-toxicity and comparable efficacy in a phase III trial ofpegylated li-posomal doxorubicin HCl ( CAELYX/Doxil) versus conventionaldoxorubicin for first-line treatment ofmetastatic breast cancer[ J ].Ann Oncol, 2004,15(3) : 440 -449. 被引量：1
9ANNE M , JEREMY W, MICHAEL L,et al. A phase II nonran-domized open-label study of liposomal daunorubicin ( DaunoX-ome) in advanced soft tissue sarcoma [ J ]. Sarcoma, 2006,1(1):1 -5. 被引量：1
10STATHOPOULOS GP.ANTONIOU D , DIMITROULIS J,et al.Liposomal cisplatin combined with paclitaxel versus cisplatin andpaclitaxel in non-small-cell lung cancer: a randomized phase IIImulticenter trial[ J]. Ann Oncol,2010,21(11) : 2227 -2232. 被引量：1
